Over a Decade of Innovation

We are pioneering a new era of medicines

Transforming the lives of patients living with serious diseases

First-Ever Approved CRISPR-Based Therapy

CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, is approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia.

Rapidly translating a revolutionary technology into therapies

Innovation that matters

Rapidly translating a revolutionary technology into therapies

Learn more about gene editing
Science crispr x

Pushing the bounds of science

We are pioneers of the CRISPR technology and at the forefront of what’s next

Learn more about CRISPR-X

Committed to patients

Developing gene-based medicines with the potential to transform the lives of people with serious diseases

Patient Advocacy

CRISPR Therapeutics Corporate Presentation

View our corporate presentation to learn more about our company.

Download Here

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.